Candel Therapeutics (CADL) Change in Accured Expenses (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Change in Accured Expenses data on file, last reported at $2.3 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Accured Expenses rose 320.77% year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2025 stood at $2.3 million (up 197.75% YoY), and the FY2025 full-year result was $2.3 million, up 197.75% from the prior year.
• Change in Accured Expenses rose to $2.3 million in Q4 2025, from $1.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q4 2025 to a low of -$2.4 million in Q1 2025.
• A 5-year average of $213600.0 and a median of $493500.0 in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses plunged 2088.89% in 2023 and jumped 1692.94% in 2024, its largest moves.
• Tracing CADL's Change in Accured Expenses over 5 years: stood at $719000.0 in 2021, then tumbled by 39.5% to $435000.0 in 2022, then jumped by 117.47% to $946000.0 in 2023, then slumped by 42.49% to $544000.0 in 2024, then surged by 320.77% to $2.3 million in 2025.
• Business Quant data shows CADL's Change in Accured Expenses at $2.3 million in Q4 2025, $1.2 million in Q3 2025, and $1.1 million in Q2 2025.